CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00453310
NCT00453310Phase 2Completed
CompareCT.gov

A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors

Memorial Sloan Kettering Cancer Center·interventional·Posted Mar 28, 2007·Updated Oct 27, 2015

In Brief

A Phase 2 clinical trial evaluating sunitinib malate for Extragonadal Germ Cell Tumor and 3 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with metastatic germ cell tumors that have relapsed or not responded to treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Pfizer

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 28, 2007
Enrollment StartMar 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.3 years ago

Interventions

sunitinib malatedrug